Literature DB >> 31388721

Comparative dosimetry between 99mTc-MAA SPECT/CT and 90Y PET/CT in primary and metastatic liver tumors.

Alexandre Jadoul1, Claire Bernard2, Pierre Lovinfosse2, Laurent Gérard3, Henri Lilet2, Olivier Cornet3, Roland Hustinx2.   

Abstract

INTRODUCTION: The aim of this study is to determine whether 99mTc-MAA SPECT/CT-based dosimetry could predict the actual absorbed dose in hepatocellular carcinoma (HCC) or liver metastases, treated by glass or resin microspheres.
MATERIAL AND METHODS: Fifty-seven patients who underwent selective internal radiation therapy (SIRT) were retrospectively included in the study, for a total of 59 treatments. Nineteen HCC were treated by resin microspheres (HCC-SIR), 20 HCC with glass microspheres (HCC-Thera), and 20 liver metastases with resin microspheres (Metastases-SIR). The mean absorbed doses in tumoral liver (Dm) and non-tumoral liver (DmNTL) were determined on the 99mTc-MAA SPECT/CT and the 90Y PET/CT, and compared with each other.
RESULTS: DmNTL was < 50 Gy in the 3 groups, with a strong correlation in all population, albeit slightly lower in Metastases-SIR than HCC-SIR and HCC-Thera (CCC 0.8, 0.94 and 0.96, respectively). In tumoral liver, Dm was higher in HCC than metastases (159 ± 117 Gy versus 63 ± 31 Gy). 99mTc-MAA SPECT/CT proved to be a better indicator of Dm in HCC compared with metastases, with similar 99mTc-MAA-90Y concordance in resin and glass microspheres (CCC HCC-SIR 0.82, CCC HCC-Thera 0.82, and CCC Metastases-SIR 0.52).
CONCLUSION: 99mTc-MAA SPECT/CT is a reasonably reliable tool for predicting the dose to the non-tumoral liver in both HCC and metastases, regardless of the type of microspheres. It is also fairly reliable for predicting the tumor dose in HCC, again regardless of the type of spheres, although individual variations are observed.

Entities:  

Keywords:  Dosimetry; Hepatocarcinoma; Liver metastases; Microspheres; Radioembolization

Mesh:

Substances:

Year:  2019        PMID: 31388721     DOI: 10.1007/s00259-019-04465-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  35 in total

Review 1.  SIRT of liver metastases: physiological and pathophysiological considerations.

Authors:  Christophe Van de Wiele; Alex Maes; Eddy Brugman; Yves D'Asseler; Bart De Spiegeleer; Gilles Mees; Karin Stellamans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-07-17       Impact factor: 9.236

2.  Negative phase 3 study of 90Y microspheres versus sorafenib in HCC.

Authors:  Etienne Garin; Yan Rolland; Boris Campillo-Gimenez; Julien Edeline
Journal:  Lancet Oncol       Date:  2018-02       Impact factor: 41.316

3.  Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer.

Authors:  S Ho; W Y Lau; T W Leung; M Chan; P J Johnson; A K Li
Journal:  Eur J Nucl Med       Date:  1997-03

4.  Correlation of Technetium-99m Macroaggregated Albumin and Yttrium-90 Glass Microsphere Biodistribution in Hepatocellular Carcinoma: A Retrospective Review of Pretreatment Single Photon Emission CT and Posttreatment Positron Emission Tomography/CT.

Authors:  Paul Haste; Mark Tann; Scott Persohn; Thomas LaRoche; Vasantha Aaron; Thibault Mauxion; Nikhil Chauhan; Matthew R Dreher; Matthew S Johnson
Journal:  J Vasc Interv Radiol       Date:  2017-02-24       Impact factor: 3.464

5.  Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.

Authors:  Etienne Garin; Yan Rolland; Julien Edeline; Nicolas Icard; Laurence Lenoir; Sophie Laffont; Habiba Mesbah; Mathias Breton; Laurent Sulpice; Karim Boudjema; Tanguy Rohou; Jean-Luc Raoul; Bruno Clement; Eveline Boucher
Journal:  J Nucl Med       Date:  2015-02-12       Impact factor: 10.057

6.  Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres.

Authors:  Patrick Flamen; Bruno Vanderlinden; Philippe Delatte; Ghanem Ghanem; Lieveke Ameye; Marc Van Den Eynde; Alain Hendlisz
Journal:  Phys Med Biol       Date:  2008-10-31       Impact factor: 3.609

7.  Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.

Authors:  Valérie Vilgrain; Helena Pereira; Eric Assenat; Boris Guiu; Alina Diana Ilonca; Georges-Philippe Pageaux; Annie Sibert; Mohamed Bouattour; Rachida Lebtahi; Wassim Allaham; Hélène Barraud; Valérie Laurent; Elodie Mathias; Jean-Pierre Bronowicki; Jean-Pierre Tasu; Rémy Perdrisot; Christine Silvain; René Gerolami; Olivier Mundler; Jean-Francois Seitz; Vincent Vidal; Christophe Aubé; Frédéric Oberti; Olivier Couturier; Isabelle Brenot-Rossi; Jean-Luc Raoul; Anthony Sarran; Charlotte Costentin; Emmanuel Itti; Alain Luciani; René Adam; Maïté Lewin; Didier Samuel; Maxime Ronot; Aurelia Dinut; Laurent Castera; Gilles Chatellier
Journal:  Lancet Oncol       Date:  2017-10-26       Impact factor: 41.316

8.  Post-radioembolization yttrium-90 PET/CT - part 2: dose-response and tumor predictive dosimetry for resin microspheres.

Authors:  Yung-Hsiang Kao; Jeffrey D Steinberg; Young-Soon Tay; Gabriel Ky Lim; Jianhua Yan; David W Townsend; Charley A Budgeon; Jan A Boucek; Roslyn J Francis; Timothy St Cheo; Mark C Burgmans; Farah G Irani; Richard Hg Lo; Kiang-Hiong Tay; Bien-Soo Tan; Pierce Kh Chow; Somanesan Satchithanantham; Andrew Eh Tan; David Ce Ng; Anthony Sw Goh
Journal:  EJNMMI Res       Date:  2013-07-25       Impact factor: 3.138

9.  A Comparison of Techniques for (90)Y PET/CT Image-Based Dosimetry Following Radioembolization with Resin Microspheres.

Authors:  Alexander S Pasciak; Austin C Bourgeois; Yong C Bradley
Journal:  Front Oncol       Date:  2014-05-22       Impact factor: 6.244

10.  Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept.

Authors:  E Garin; L Lenoir; J Edeline; S Laffont; H Mesbah; P Porée; L Sulpice; K Boudjema; M Mesbah; A Guillygomarc'h; E Quehen; M Pracht; J L Raoul; B Clement; Y Rolland; E Boucher
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-24       Impact factor: 9.236

View more
  9 in total

1.  Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group.

Authors:  Riad Salem; Siddharth A Padia; Marnix Lam; Carlo Chiesa; Paul Haste; Bruno Sangro; Beau Toskich; Kirk Fowers; Joseph M Herman; S Cheenu Kappadath; Thomas Leung; Daniel Y Sze; Edward Kim; Etienne Garin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-09-17       Impact factor: 10.057

2.  Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases.

Authors:  Sander C Ebbers; Caren van Roekel; Manon N G J A Braat; Maarten W Barentsz; Marnix G E H Lam; Arthur J A T Braat
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-12-07       Impact factor: 9.236

3.  Diagnostic and prognostic value of 99mTc-MAA SPECT/CT for treatment planning of 90Y-resin microsphere radioembolization for hepatocellular carcinoma: comparison with planar image.

Authors:  Mai Hong Son; Le Ngoc Ha; Mai Hong Bang; Sungwoo Bae; Dinh Truong Giang; Nguyen Tien Thinh; Jin Chul Paeng
Journal:  Sci Rep       Date:  2021-02-05       Impact factor: 4.379

4.  Impact of contouring methods on pre-treatment and post-treatment dosimetry for the prediction of tumor control and survival in HCC patients treated with selective internal radiation therapy.

Authors:  Jean Marc Vrigneaud; Alexandre Cochet; Guillaume Nodari; Romain Popoff; Jean Marc Riedinger; Olivier Lopez; Julie Pellegrinelli; Inna Dygai-Cochet; Claire Tabouret-Viaud; Benoit Presles; Olivier Chevallier; Sophie Gehin; Matthieu Gallet; Marianne Latournerie; Sylvain Manfredi; Romaric Loffroy
Journal:  EJNMMI Res       Date:  2021-03-09       Impact factor: 3.138

5.  Impact of the dosimetry approach on the resulting 90Y radioembolization planned absorbed doses based on 99mTc-MAA SPECT-CT: is there agreement between dosimetry methods?

Authors:  Verónica Morán; Elena Prieto; Lidia Sancho; Macarena Rodríguez-Fraile; Leticia Soria; Arantxa Zubiria; Josep M Martí-Climent
Journal:  EJNMMI Phys       Date:  2020-12-07

6.  EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.

Authors:  M Weber; M Lam; C Chiesa; M Konijnenberg; M Cremonesi; P Flamen; S Gnesin; L Bodei; T Kracmerova; M Luster; E Garin; K Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-02-11       Impact factor: 9.236

7.  A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study.

Authors:  Marnix Lam; Etienne Garin; Marco Maccauro; S Cheenu Kappadath; Daniel Y Sze; Cuneyt Turkmen; Murat Cantasdemir; Paul Haste; Ken Herrmann; Hamad Saleh Alsuhaibani; Matthew Dreher; Kirk D Fowers; Riad Salem
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-04-08       Impact factor: 10.057

Review 8.  Personalised Dosimetry in Radioembolisation for HCC: Impact on Clinical Outcome and on Trial Design.

Authors:  Etienne Garin; Xavier Palard; Yan Rolland
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639

9.  Inter-observer variability of 90Y PET/CT dosimetry in hepatocellular carcinoma after glass microspheres transarterial radioembolization.

Authors:  Nicolas Meyers; Alexandre Jadoul; Claire Bernard; Jean Delwaide; Anne Lamproye; Olivier Detry; Pierre Honoré; Laurent Gerard; Roland Hustinx
Journal:  EJNMMI Phys       Date:  2020-05-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.